Last reviewed · How we verify
SHR7280
At a glance
| Generic name | SHR7280 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects (PHASE3)
- A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects (PHASE1)
- A Trial of SHR7280 in Healthy Subjects (PHASE1)
- A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers (PHASE1)
- The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis. (PHASE1, PHASE2)
- Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) (PHASE2)
- A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids (PHASE2, PHASE3)
- A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR7280 CI brief — competitive landscape report
- SHR7280 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI